Audit: QRS - Pueraria mirifica for Health & Longevity
Audit conducted on 20/08/2026 23:19 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Spot-checked across every populated span: protocol doses, time-to-effect windows, benefit/risk labels, all twelve monitoring targets, and the cadence trace verbatim or near-verbatim to ER lines 158-206, 234-292, 344-351, 377-381, 434, 462-487. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Cautious ER framing is carried through: “never tested in a controlled study” (at-a-glance) mirrors ER line 511; “a second found no lipid benefit” (time_3_sub) mirrors ER line 178; bone claim kept as “reduced bone turnover”, not bone density, matching the ER surrogate-endpoint caveat at line 172. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | No strengthening or softening found; absolute contraindications (SERMs, aromatase inhibitors) stay absolute in the Contraindications gate, and cautions stay in Key Interactions. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications derive only from the ER avoid-list and the two absolute drug contraindications; no Benefit- or Risk-Modifying Factor is re-surfaced as a gate item. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | The QRS carries no PMIDs, citations, expert names, NCT identifiers, or brand names. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attribution appears anywhere in the sheet; the Restorative Medicine attribution attached to the extract protocol in ER line 379 is correctly dropped rather than re-stated. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Matches the ER register: measured, conflict-naming, non-promotional. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Expert and data-driven (numeric targets, dose ranges) while remaining accessible; conflicts are named rather than hidden. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Presents evidence and thresholds; no prescriptive instruction to a patient. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Content is framed as what the evidence shows and what was measured, not as instruction. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Protocol and cadence cells describe the regimens used in trials rather than recommending them. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person address anywhere in the sheet. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms retained are the ER own biomarker and benefit labels; nothing gratuitous is added. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Gate items, benefit and risk tiers, and monitoring rows are all stripped to the key fact. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed by scan: no “you”/”your” in any populated span. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Framing (marker-assayed material, functional biomarker targets, monitoring cadence) targets the proactive, risk-aware reader. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Assumes willingness to run baseline panels, transvaginal ultrasound, and a twelve-marker monitoring programme. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Not pitched at a general-population reader; the monitoring and sourcing burden is substantial. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Risk weighting reflects the longevity audience: the C-reactive protein rise and the batch-potency variance are surfaced as first-order concerns. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | The term “anti-aging” does not appear. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Clinical register throughout (“vaginal atrophy”, “climacteric symptoms”, “endometrial thickness”); the plain-language at-a-glance follows ER conclusion wording as item 7.4 requires. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” Gate headings: “Contraindications”, “Key Interactions” Tier labels: “High”, “Medium”, “Low”, “Speculative” Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed headings present and unmodified: Protocol, Time to effect, Benefits, Risk & Side Effects, Monitoring, Qualitative Assessment, Contraindications, Key Interactions, the four tier labels, and Marker/Target/Why. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | 77 data-qrs-var spans present, covering every variable region the checklist addresses (header 4, at-a-glance 1, action 9, time 9, benefits 4, gates 2, risks 4, markers 36, cadence 1, qualitative 7). |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Non-checklist template elements are untouched, including the website=”evidence_review”, website=”audit”, and website=”full_review” spans and the footer disclaimer. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No section of the source ER is empty; every section the QRS draws on carries content, so no empty-state phrasing is required. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol cell labels reproduce the ER bold labels verbatim: “Standard oral protocol”, “Local genitourinary protocol”, “Competing extract protocol” (ER lines 377-381). |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | No label is paraphrased or invented; time-to-effect labels use the ER own terms from line 434. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | Scan confirms no emoji anywhere in the file; tier emphasis is carried by bold labels and CSS only. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed rather than extended: gate items are stripped of rationale, benefit and risk entries reduced to bare labels, monitoring targets and rationales cut to one clause each, and the cadence paragraph compressed from ER line 462. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | The metadata comment opens at line 2, immediately after <!doctype html>, before any other content. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | YAML opens at line 3 and closes at line 13; the preceding descriptive text sits outside the delimiters. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment and duplicated nowhere on the sheet. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All values trimmed; only duration is quoted, which is required because the value contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: pueraria_mirifica_2026-0825-2054_Opus_ER.md, matching the source ER. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching this prompt version. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0820-2305, in the required format. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | Single word, no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | Nickname plus version number, no additional qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9: qrs_filename matches the actual filename of the document. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | No stray whitespace or unnecessary quoting in any value. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Pueraria mirifica for Health & Longevity - Quick Reference Sheet”, with the ampersand entity-encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “Pueraria mirifica for Health & Longevity”, matching the ER canonical_topic. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: 08/20/2026, correctly derived from qrs_creation_date 2026-0820-2305. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: Opus 5, matching qrs_creator_ai_fullname. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header carries only the title and the standard subline; no badge, version stamp, alternate-names line, or audit date. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Distils the ER Conclusion (lines 511-513) into the local finding, the weakly supported wider claims, the untested consumer use, and the two safety caveats. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | Exactly 60 words, at the limit. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each clause traces to a distinct ER Conclusion passage: root/estrogen (line 511), local finding (line 511), wider claims (line 511), breast enlargement (line 511), unsettled safety and batch variance (line 513). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | Uses “the body’s own estrogen”, “dummy-treatment comparison”, and “batch strength” rather than receptor, placebo, or standardisation jargon; no acronyms appear. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years, or sample sizes. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No effect sizes, relative risks, or statistics. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Drawn from the ER Key Interactions & Contraindications section, lines 316-351. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All eight ER avoid-list populations plus the two absolute drug contraindications (SERMs, aromatase inhibitors) are present, in ER order. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | All ten items are individual <li> elements inside the stop_items span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Trailing rationale is stripped throughout: ER “Men, in whom no efficacy has been shown and feminising effects are plausible” becomes “Men”; the bleeding-burden clause is dropped from the premenopausal item. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Qualifiers survive: “until the cause is established”, “Child-Pugh Class B or C”, “during breast-cancer treatment”, and the named gene and drug lists. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER Key Interactions & Contraindications section uses no ranking notation inside parentheses. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The section is populated, and the ER does name populations that should avoid the intervention, so the empty-state condition correctly does not apply. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The Contraindications section is not empty; it carries ten items. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Drawn from the ER Key Interactions & Contraindications section, lines 316-340. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All eleven ER interaction bullets appear, in ER order; the two absolute contraindications are correctly excluded and placed in the Contraindications gate instead. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | All eleven items are individual <li> elements inside the caution_items span. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Mechanism, consequence, and mitigation clauses from each ER bullet are stripped; only the interacting agent remains. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Example drug lists are preserved in full for estrogen therapy, QT-prolonging drugs, CYP1A2 substrates, biliary-cleared drugs, and the painkiller class. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER Key Interactions & Contraindications section uses no ranking notation inside parentheses. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The section is populated, and the ER does name interactions, so the empty-state condition correctly does not apply. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The Key Interactions section is not empty; it carries eleven items. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | Drawn from the ER Therapeutic Protocol section, lines 377-381. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | The three dosing regimens (standard oral, local genitourinary gel, competing extract) are the actionable core of that section; the remaining bullets are caveats rather than regimens. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER Therapeutic Protocol section supplies three distinct actionable regimens, so all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine action spans carry ER-derived content: 20-50 mg root powder in the morning, 0.5 g of 5-6% gel on the two-week then three-times-weekly schedule, and 200 mg extract standardised to 150 mcg miroestrol twice daily. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Vaginal dryness, climacteric symptom scores, and lipid changes are the three time-to-effect aspects the ER states (line 434). |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered high-tier benefit first (vaginal atrophy reversal), then the two medium-tier benefits in ER order (climacteric symptoms, then lipids). |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies three distinct time-to-effect aspects, so all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine time spans carry ER-derived content, including the 24-week tissue-maturation follow-on folded into time_1_sub. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information (Practical Considerations, line 434), so the section is retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Drawn from the ER Expected Benefits section, lines 154-206. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four tier variables are populated. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each entry is the bare ER benefit heading; magnitudes, trial designs, and mechanisms are dropped. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content is carried through. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four benefit tiers (high, medium, low, speculative) carry items in the ER, so no span needs hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Drawn from the ER Potential Risks & Side Effects section, lines 232-292. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four tier variables are populated. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each entry is the bare ER risk heading; magnitudes, surveillance detail, and mechanisms are dropped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content is carried through; the ER Conflicted markers are correctly not reproduced. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four risk tiers (high, medium, low, speculative) carry items in the ER, so no span needs hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Drawn from the ER Monitoring Protocol & Defining Success section, lines 460-477. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All twelve ER biomarkers are present in ER order, from follicle-stimulating hormone through vaginal pH, with targets and rationales condensed but faithful. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Cadence carries the baseline panels, the 8-12 week liver and blood count recheck, the 3- and 6-month hormone, lipid, and inflammation markers, and the annual endometrial ultrasound beyond six months. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Drawn from the qualitative marker list in the ER Monitoring Protocol & Defining Success section, lines 481-487. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All seven ER qualitative markers are present, in ER order and near-verbatim. |
Issues 20/08/2026 23:19
Pass rate 100.00%. No issues found.
Issues 20/08/2026 23:12
- 1.3 — Untested claim strengthened: [at_a_glance] at line 437 states “Breast enlargement was never tested.”, dropping the ER
Conclusionqualifier “in a controlled study” (ER line 511) and turning a bounded statement into an absolute one.
Fixes 20/08/2026 23:12
- 1.3 — Untested claim qualifier restored: Changed [at_a_glance] from “Breast enlargement was never tested.” to “Breast enlargement was never tested in a controlled study.”, matching the ER
Conclusion; “Safety is unsettled, and batch strength varies widely.” was tightened to “Safety is unsettled; batch strength varies widely.” to keep the passage within the 60-word budget.